Skip to content

LASIK Using Contoura With Phorcides vs. iDesign

Comparison of Clinical Outcomes of LASIK Using Contoura With Phorcides vs. iDesign

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07128316
Enrollment
63
Registered
2025-08-18
Start date
2023-09-11
Completion date
2025-12-15
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Astigmatism, Myopia

Brief summary

Participants will undergo LASIK using Contoura with Phorcides calculation on one eye and LASIK using iDesign calculation on the contralateral eye to correct myopia.

Detailed description

Once consented to participate in the study, subjects will have a comprehensive ocular examination to determine eligibility to undergo LASIK using Contoura with Phorcides calculation on one eye and LASIK using iDesign calculation on the contralateral eye to correct myopia. The study objective is to compare the 6-month visual outcomes (i.e., visual acuity, contract sensitivity, high order aberrations), quality of vision (i.e., double vision, glare, starburst, halos, etc.) and dry eye symptoms of patients undergoing contralateral LASIK using Contoura with Phorcides calculation vs. LASIK using iDesign calculation. Surgical treatment will be randomized so there is a 50% chance to receive LASIK using Contoura with Phorcides vs LASIK using iDesign calculation on the contralateral eye. Subjects will receive standard of care topical ophthalmic antibiotic and steroid drops. This will be a prospective randomized double blind contralateral study. The patient and the staff doing the post-op evaluations will be blinded to which eye received which treatment.

Interventions

DEVICEContoura Topolyzer with Phorcides

LASIK calculated ablation using Contoura Topolyzer with Phorcides

DEVICEiDesign

LASIK calculated ablation using iDesign Refractive Studio 2.0

Sponsors

59th Medical Wing
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

This is a prospective randomized double blind contralateral study. The patient and the staff doing the post-op evaluations will be blinded to which eye received which treatment.

Intervention model description

Prospective randomized contralateral study.

Eligibility

Sex/Gender
ALL
Age
21 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Male and Females between the ages of 21 and 50 * Nearsightedness between -2.00 diopters and -8.00 diopters * Have similar levels of nearsightedness in each eye (1.5D of difference between eyes) * Less than or equal to 3.00 diopters of astigmatism * Have similar levels of astigmatism in each eye (0.75D of difference between eyes) * Total spherical equivalent (SE) of no more than -9.0 D * Tricare Prime or Tricare Select Beneficiary * Residing within 60 miles radius from Lackland AFB

Exclusion criteria

* Subjects with corneal abnormal findings including signs of keratoconus, keratoconus suspect, abnormal corneal topography, epithelial basement membrane disease, pellucid marginal degeneration, corneal degenerations, progressive and unstable myopia, irregular or unstable corneal mires on central keratometry images, and patients whose corneal thickness would cause anticipated treatment would violate the posterior 250 microns of corneal stroma from the corneal endothelium. * Subjects with any ocular disease such as advanced/uncontrolled glaucoma, severe dry eye, active eye infection or inflammation, recent herpes eye infection or problems resulting from past infection. * Subjects with active collagen vascular, connective tissue, autoimmune or immunodeficiency diseases * Pregnant or nursing females * Systemic disease likely to affect wound healing, such as diabetes and severe atopy * Taking the medication Isotretinoin (Accutane) or antimetabolites for any medical condition

Design outcomes

Primary

MeasureTime frameDescription
Percentage of eyes with Uncorrected Visual Acuity of 20/16 or better at 6-month Post-Op6-month Post-OpPost-operative uncorrected visual acuity of 20/16 or better measure with ETDRS chart; unit = percentage eyes with Uncorrected Visual Acuity.

Secondary

MeasureTime frameDescription
Change in high contrast visual acuity at 6-month Post-OpChange from baseline (pre-op) to 6-month Post-OpChange in the mean uncorrected visual acuity (unit = logMAR) measure with ETDRS chart from baseline (pre-op) at 6 months post-op.
Change in refractive error at 6-month Post-OpChange from baseline (pre-op) to 6-month Post-OpChange in the mean refractive error measure with phoropter (unit = diopters) from baseline (pre-op) at 6 months post-op.

Other

MeasureTime frameDescription
Change in low contrast visual acuity at 6-month Post-OpChange from baseline (pre-op) to 6-month Post-OpChange in the mean low contrast visual acuity (unit = logMAR) measure with ETDRS 5% chart from baseline (pre-op) at 6 months post-op.
Change in mean score Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire at 6-month Post-OpChange from baseline (pre-op) to 6-month Post-OpThe SPEED is a validated tool to assess self-reported dry eye symptoms. Possible dry eye symptoms score ranges from 0 (never) to 3 (Constant). Higher value indicates worse dry eye symptoms.
Change in higher order aberrations at 6-month Post-OpChange from baseline (pre-op) to 6-month Post-OpChange in the mean higher order aberrations (unit = root mean square) measure with iDesign 2.0 Refractive Studio from baseline (pre-op) at 6 months post-op.
Change in mean score Patient-Reported Outcomes with LASIK Symptoms and Satisfaction (PROWL-SS) Questionnaire at 6-month Post-OpChange from baseline (pre-op) to 6-month Post-OpThe PROWL-SS is a validated tool to assess self-reported symptoms and satisfaction after refractive surgery. Possible Satisfaction Score ranges from 1 (completely satisfied) to 6 (completely dissatisfied). Lower value indicates higher satisfaction. Possible Symptoms Score ranges from 1 (extremely bothersome) to 5 (not at all bothersome). Lower value indicates worse symptoms.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026